MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-21-2025
Quest Diagnostics Incorporated Balance Sheet 2011-2026 | DGX
Annual Balance Sheet Quest Diagnostics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
5.24 B | 3.88 B | 3.82 B | 3.29 B | 3 B | 3.58 B | 3.76 B | 3.65 B | 3.38 B | 3.52 B | 3.57 B | 3.14 B | 3.07 B | 3.86 B |
Long Term Debt |
5.62 B | 4.41 B | 3.98 B | 4.01 B | 4.01 B | 3.97 B | 3.43 B | 3.75 B | 3.73 B | 3.49 B | 3.24 B | 3.12 B | 3.35 B | 3.37 B |
Long Term Debt Current |
173 M | 153 M | 153 M | 151 M | 141 M | 145 M | 464 M | 36 M | 6 M | 159 M | 518 M | 212 M | 9.4 M | 569 M |
Total Non Current Liabilities |
- | - | - | - | - | 5.17 B | 4.25 B | 4.49 B | 4.46 B | 4.08 B | 3.84 B | 3.84 B | 4.05 B | 4.04 B |
Total Current Liabilities |
2.17 B | 1.82 B | 1.55 B | 1.75 B | 1.78 B | 1.99 B | 1.48 B | 1.06 B | 981 M | 1.17 B | 1.71 B | 1.13 B | 1.05 B | 1.56 B |
Total Liabilities |
- | - | - | - | - | 7.16 B | 5.74 B | 5.55 B | 5.44 B | 5.25 B | 5.55 B | 4.98 B | 5.1 B | 5.6 B |
Retained Earnings |
9.36 B | 8.82 B | 8.29 B | 7.65 B | 9.3 B | 8.17 B | 7.6 B | 7.14 B | 6.61 B | 6.2 B | 5.72 B | 5.36 B | 4.69 B | 4.26 B |
Total Assets |
16.2 B | 14 B | 12.8 B | 13.6 B | 14 B | 12.8 B | 11 B | 10.5 B | 10.1 B | 9.96 B | 9.88 B | 8.95 B | 9.28 B | 9.31 B |
Cash and Cash Equivalents |
549 M | 686 M | 315 M | 872 M | 1.16 B | 1.19 B | 135 M | 137 M | 359 M | 133 M | 192 M | 187 M | 296 M | 165 M |
Book Value |
16.2 B | 14 B | 12.8 B | 13.6 B | 14 B | 5.69 B | 5.27 B | 4.96 B | 4.66 B | 4.71 B | 4.33 B | 3.97 B | 4.19 B | 3.71 B |
Total Shareholders Equity |
6.78 B | 6.31 B | 5.93 B | 6.48 B | 6.81 B | 5.64 B | 5.22 B | 4.92 B | 4.63 B | 4.68 B | 4.3 B | 3.95 B | 4.16 B | 3.69 B |
All numbers in USD currency
Quarterly Balance Sheet Quest Diagnostics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5.17 B | 5.17 B | 5.86 B | 5.65 B | 3.82 B | 3.8 B | 3.95 B | 3.78 B | 3.98 B | 3.98 B | 3.98 B | - | 3.98 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 4.02 B | 4.02 B | 4.03 B | 3.97 B | 3.97 B | 3.97 B | 3.97 B | 3.43 B | 3.43 B | 3.43 B | 3.43 B | 3.75 B | 3.75 B | 3.75 B | 3.75 B | 3.73 B | 3.82 B | 3.84 B | 3.74 B | 3.49 B | 3.49 B | 3.49 B | 3.49 B | 3.22 B | 3.22 B | 3.22 B | 3.24 B | 3.12 B | 3.33 B | 3.33 B | 3.33 B | 3.36 B | 3.35 B | 3.35 B | 3.35 B | 3.94 B | 3.37 B | 3.37 B | 3.37 B |
Retained Earnings |
9.84 B | 9.68 B | 9.49 B | 9.22 B | 9.08 B | 8.94 B | 8.71 B | 8.57 B | 8.41 B | 8.29 B | 8.26 B | - | 7.93 B | 7.65 B | 7.33 B | 10.2 B | 9.69 B | 9.3 B | 9.3 B | 9.3 B | 9.3 B | 8.17 B | 8.17 B | 8.17 B | 8.17 B | 7.6 B | 7.6 B | 7.6 B | 7.6 B | 7.14 B | 7.14 B | 7.14 B | 7.14 B | 6.61 B | 6.61 B | 6.61 B | 6.61 B | 6.2 B | 6.2 B | 6.2 B | 6.2 B | 5.72 B | 5.72 B | 5.72 B | 5.72 B | 5.36 B | 5.36 B | 5.36 B | 5.36 B | 4.69 B | 4.69 B | 4.69 B | 4.69 B | 4.26 B | 4.26 B | 4.26 B | 4.26 B |
Total Assets |
16.2 B | 16 B | 15.8 B | 16.1 B | 13.9 B | 14 B | 13.5 B | 13.4 B | 12.8 B | 12.8 B | 13.2 B | - | 13.4 B | 13.6 B | 13.6 B | 12.9 B | 13.9 B | 14 B | 14 B | 14 B | 14 B | 12.8 B | 12.8 B | 12.8 B | 12.8 B | 11 B | 11 B | 11 B | 11 B | 10.5 B | 10.5 B | 10.5 B | 10.5 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.96 B | 9.96 B | 9.96 B | 9.96 B | 9.86 B | 9.86 B | 9.86 B | 9.88 B | 8.95 B | 8.95 B | 8.95 B | 8.95 B | 9.28 B | 9.28 B | 9.28 B | 9.28 B | 9.31 B | 9.31 B | 9.31 B | 9.31 B |
Cash and Cash Equivalents |
432 M | 319 M | 188 M | 764 M | 271 M | 474 M | 143 M | 126 M | 175 M | 315 M | 700 M | 790 M | 712 M | 872 M | 987 M | 560 M | 1.23 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 1.19 B | 1.19 B | 1.19 B | 1.19 B | 135 M | 135 M | 135 M | 135 M | 137 M | 137 M | 137 M | 137 M | 359 M | 359 M | 359 M | 359 M | 133 M | 133 M | 133 M | 133 M | 192 M | 192 M | 192 M | 192 M | 187 M | 187 M | 187 M | 187 M | 296 M | 296 M | 296 M | 296 M | 165 M | 165 M | 165 M | 165 M |
Book Value |
16.2 B | 16 B | 15.8 B | 16.1 B | 13.9 B | 14 B | 13.5 B | 13.4 B | 12.8 B | 12.8 B | 13.2 B | - | 13.4 B | 13.6 B | 13.6 B | 12.9 B | 13.9 B | 14 B | 14 B | 14 B | 14 B | 12.8 B | 12.8 B | 12.8 B | 12.8 B | 11 B | 11 B | 11 B | 11 B | 10.5 B | 10.5 B | 10.5 B | 10.5 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 9.96 B | 9.96 B | 9.96 B | 9.96 B | 9.86 B | 9.86 B | 9.86 B | 9.88 B | 8.95 B | 8.95 B | 8.95 B | 8.95 B | 9.28 B | 9.28 B | 9.28 B | 9.28 B | 9.31 B | 9.31 B | 9.31 B | 9.31 B |
Total Shareholders Equity |
7.26 B | 7.23 B | 6.93 B | 6.84 B | 6.66 B | 6.47 B | 6.46 B | 6.29 B | 6.09 B | 5.89 B | 6.27 B | 6.45 B | 6.42 B | 6.44 B | 6.43 B | 5.9 B | 6.74 B | 6.76 B | 6.76 B | 6.76 B | 6.76 B | 5.64 B | 5.64 B | 5.64 B | 5.64 B | 5.22 B | 5.22 B | 5.22 B | 5.22 B | 4.92 B | 4.92 B | 4.92 B | 4.92 B | 4.63 B | 4.63 B | 4.63 B | 4.63 B | 4.68 B | 4.68 B | 4.68 B | 4.68 B | 4.3 B | 4.3 B | 4.3 B | 4.3 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 4.16 B | 4.16 B | 4.16 B | 4.16 B | 3.69 B | 3.69 B | 3.69 B | 3.69 B |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Quest Diagnostics Incorporated, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
$ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
$ 20.15 | -2.3 % | $ 217 M |  China |
 |
Co-Diagnostics
CODX
|
$ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
$ 228.92 | -0.76 % | $ 167 B | USA |
 |
BioNano Genomics
BNGO
|
$ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
DexCom
DXCM
|
$ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
Castle Biosciences
CSTL
|
$ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 11.38 | 6.36 % | $ 323 M | Israel |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
$ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
$ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
IQVIA Holdings
IQV
|
$ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Celcuity
CELC
|
$ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.12 | - | $ 99.5 K | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
$ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Myriad Genetics
MYGN
|
$ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
$ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Illumina
ILMN
|
$ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
National Research Corporation
NRC
|
$ 18.77 | 0.64 % | $ 461 M | USA |
|
Biodesix
BDSX
|
$ 6.8 | 1.19 % | $ 882 M | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
$ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
$ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 394.19 | -1.42 % | $ 29.6 B |  Schweiz |
 |
Precipio
PRPO
|
$ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Agilent Technologies
A
|
$ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Personalis
PSNL
|
$ 7.96 | -0.13 % | $ 472 M | USA |
 |
Biomerica
BMRA
|
$ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
Bioventus
BVS
|
$ 7.44 | -0.13 % | $ 466 M | USA |